TABLE 2.
Surgical and Chemotherapy Data
| Total n = 274 | FLX n = 183 | GNP n = 91 | P | |
|---|---|---|---|---|
| NAC cycles, median (IQR) | 4 (3–6) | 5 (4–6) | 3 (2–4) | <0.001* |
| Neoadjuvant RT, n = 270 | 78 (28.9) | 44 (24.4) | 34 (37.8) | 0.032* |
| SBRT | 17 (6.3) | 17 (6.3) | 6 (6.6) | 0.145 |
| Conventional | 62 (22.8) | 35 (19.3) | 27 (29.7) | |
| AC | 179 (67.8) | 130 (72.6) | 49 (57.6) | 0.017* |
| FLX | 29 (11) | 29 (16.7) | 0 | <0.001* |
| GNP | 35 (13.3) | 18 (10.3) | 17 (19.1) | |
| Gemcitabine | 69 (26.2) | 51 (29.3) | 18 (20.2) | |
| Other/unknown | 46 (25.7) | 32 (24.6) | 14 (28.6) | |
| AC cycles, median (IQR) | 4 (3–6) | 4 (3–6) | 4 (3–6) | 0.214 |
| Adjuvant RT | 47 (17.3) | 36 (19.9) | 11 (12.1) | 0.127 |
| SBRT | 3 (1.1) | 3 (1.7) | 0 | 0.177 |
| Conventional | 41 (15.1) | 31 (17.1) | 10 (11) | |
| Type of operation | ||||
| PD | 217 (79.2) | 141 (77) | 76 (83.5) | |
| Classic | 147 (67.8) | 92 (65.2) | 55 (72.4) | |
| Pylorus-preserving | 70 (32.2) | 49 (34.8) | 21 (27.6) | 0.189 |
| DP | 40 (14.5) | 30 (16.4) | 10 (10.9) | |
| TP | 7 (2.6) | 6 (3.3) | 1 (1.1) | |
| Other | 10 (3.7) | 6 (3.2) | 4 (4.4) | |
| Minimally invasive | 8 (2.9) | 5 (2.7) | 3 (3.3) | 0.628 |
| Vein resection (n = 271) | 94 (34.7) | 68 (37.8) | 26 (28.6) | 0.132 |
| Estimated blood loss, mL, median (IQR) | 400 (200–750) | 400 (200–750) | 400 (150–700)x | 0.369 |
| Operative time, min, median (IQR) | 364 (245–459) | 377 (261–476) | 324 (208–436) | 0.036* |
| ICU stay, d, median (IQR) | 0 (0–2) | 0 (0–1) | 0 (0–2) | 0.236 |
| Hospital stay, d, median (IQR) | 7 (6–10) | 7 (5–9) | 8 (6–11) | 0.355 |
| 30-day mortality | 6 (2.2) | 5 (2.7) | 1 (1.1) | 0.667 |
| 90-day Clavien-Dindo morbidity score | ||||
| None | 119 (43.4) | 80 (43.7) | 39 (42.9) | |
| I | 52 (19) | 41 (22.5) | 11 (12.1) | |
| II | 67 (24.5) | 40 (21.9) | 27 (29.7) | 0.065 |
| III | 25 (9.1) | 16 (8.7) | 9 (9.8) | |
| IV | 5 (1.8) | 1 (0.5) | 4 (4.4) | |
| V | 6 (2.2) | 5 (2.7) | 1 (1.1) | |
| Pancreatic fistula (ISGPS grading) | ||||
| None | 252 (92) | 167 (91.3) | 85 (93.4) | |
| Grade A | 11 (4) | 8 (4.4) | 3 (3.3) | 0.765 |
| Grade B | 9 (3.3) | 6 (3.2) | 3 (3.3) | |
| Grade C | 2 (0.7) | 2 (1.1) | 0 |
AC indicates adjuvant chemotherapy; DP, distal pancreatectomy; FLX, FOLFIRINOX; GNP, gemcitabine/nab-paclitaxel; IQR, interquartile range; ISGPS, International Study Group in Pancreatic Surgery; NAC, neoadjuvant chemotherapy; PD, pancreaticoduodenectomy; RT, radiation; SBRT, stereotactic body radiotherapy; SD, standard deviation; TP, total pancreatectomy.
*
Statistically significant.